Development of system-level performance measures for evaluation of models of care for inflammatory arthritis in Canada

Journal of Rheumatology

Volumn 43, Issue 3, 2016, Pages 530-540

  Barber, Claire E H ^a   Marshall, Deborah A ^a,b   Mosher, Dianne P ^a   Akhavan, Pooneh ^c   Tucker, Lori ^d   Houghton, Kristin ^d   Batthish, Michelle ^e   Levy, Deborah M ^f   Schmeling, Heinrike ^b   Ellsworth, Janet ^g   Tibollo, Heidi ^h   Grant, Sean ⁱ   Khodyakov, Dmitry ⁱ   Lacaille, Diane ^d   Ahluwalia, Vandana ^j   Averns, Henry ^a   Barnabe, Cheryl ^a   Bombardier, Claire ^k   Bartlett, Susan J ^l   Bernatsky, Sasha ^l   Burt, Jennifer ^m   Feldman, Debbie ⁿ   Gladman, Dafna D ^k   Greene, Beverly ^o   Haraoui, Boulos ⁿ   Haroon, Nigil ^c   Hofstetter, Catherine ^p   Huber, Adam M ^q   Keeling, Stephanie ^g   Lang, Bianca ^q   Le Clercq, Sharon A ^a   Lupton, Theresa ^r   Lyddiatt, Anne ^aa   Mandhane, Rashmi ^r   Morishita, Kimberly ^d   Papachristos, Angelo ^s   Patrick, Patricia ^r   Richards, Dawn ^p   Robinson, David ^t   Shiff, Natalie J ^u   Taylor, Trudy ^q   Taylor Gjevre, Regina ^u   Thomson, Glen T D ^aa   Thorne, Carter ^c,v   Toupin April, Karine ^w   Tugwell, Peter ^x   Westby, Marie D ^y   Widdifield, Jessica ^l   Woodhouse, Linda ^g   Zummer, Michel ^z   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h Doctor Evidence LLC   (United States)

ⁱ RAND CORPORATION   (United States)

^j WILLIAM OSLER HEALTH SYSTEM   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l MCGILL UNIVERSITY   (Canada)

^m St Clare's Mercy Hospital   (Canada)

ⁿ UNIVERSITÉ DE MONTRÉAL   (Canada)

^o Chronic Disease Prevention Unit   (Canada)

^p Canadian Arthritis Patient Alliance   (Canada)

^q DALHOUSIE UNIVERSITY   (Canada)

^r ALBERTA HEALTH SERVICES   (Canada)

^s ST MICHAEL'S HOSPITAL   (Canada)

^t UNIVERSITY OF MANITOBA   (Canada)

^u UNIVERSITY OF SASKATCHEWAN   (Canada)

^v SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^w CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^x UNIVERSITY OF OTTAWA   (Canada)

^y VANCOUVER COASTAL HEALTH   (Canada)

^z MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^aa Dalhousie University ^*

more..

Author keywords

Ankylosing spondylitis; Juvenile idiopathic arthritis; Psoriatic arthritis; Quality indicators; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; ARTICLE; CANADA; CONSULTATION; DELPHI STUDY; DISEASE ACTIVITY; FOLLOW UP; HEALTH PRACTITIONER; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PATIENT CARE; PERFORMANCE MEASUREMENT SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRAM FEASIBILITY; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCIENTIST; TIME TO TREATMENT; VALIDITY; ARTHRITIS; HEALTH CARE QUALITY; OUTCOME ASSESSMENT; STANDARDS;

ANTIRHEUMATIC AGENTS; ARTHRITIS; CANADA; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF HEALTH CARE; RHEUMATOLOGY;

EID: 84959912279     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150839     Document Type: Article

References (50)

1. Ahluwalia V, Frank C, Mosher DP, Zummer M. A pan-Canadian approach to inflammatory arthritis models of care. [Internet. Accessed November 17, 2015.] Available from: www.arthritisalliance.ca
2. Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G. Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 2011;70:1292-5.
3. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14.
4. Kirkham B, Li W, Boggs R, Nab R, Tarallo M. Early treatment of psoriatic arthritis is associated with improved outcomes: findings from the Etanercept (Enbrel) PRESTA Trial. Arthritis Rheum 2011;63 Suppl 10:1288.
5. Haroon M, Gallagher P, Fitz Gerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2015;74:1045-50.
6. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al; Childhood Arthritis and Rheumatology Research Alliance. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
7. Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne JC, Ahluwalia V, et al. The rising burden of rheumatoid arthritis surpasses rheumatology supply in Ontario. Can J Public Health 2013;104:e450-5.
8. Kur J, Koehler B. Rheumatologist demographics in British Columbia: a looming crisis. BCMJ 2011;53:128-31.
9. Chan J, Kur J. Update on rheumatologist demographics in British Columbia. CRAJ 2014;24:15.
10. Widdifield J, Bernatsky S, Paterson JM, Thorne JC, Cividino A, Pope J, et al. Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res 2011;63:53-7.
11. Speerin R, Slater H, Li L, Moore K, Chan M, Dreinhöfer K, et al. Moving from evidence to practice: models of care for the prevention and management of musculoskeletal conditions. Best Pract Res Clin Rheumatol 2014;28:479-515.
12. Arthritis Alliance of Canada. Arthritis Alliance of Canada. [Internet. Accessed November 17, 2015.] Available from: arthritisalliance.ca/en
13. Health Quality Council of Alberta. The Alberta quality matrix for health. [Internet. Accessed November 17, 2015.] Available from: hqca.ca/about/how-we-work/the-alberta-quality-matrix-for-health-1/
14. PRISMA. Transparent reporting of systematic reviews and meta-analyses. [Internet. Accessed November 17, 2015.] Available from: www.prisma-statement.org
15. Dalal S, Khodyakov D, Srinivasan R, Straus SG, Adams JL. Expert Lens: a system for eliciting opinions from a large pool of non-collocated experts with diverse knowledge. Technol Forecast Soc 2011;78:1426-44.
16. Khodyakov D, Hempel S, Rubenstein L, Shekelle P, Foy R, Salem-Schatz S, et al. Conducting online expert panels: a feasibility and experimental replicability study. BMC Med Res Methodol 2011;11:174.
17. Rubenstein L, Khodyakov D, Hempel S, Danz M, Salem-Schatz S, Foy R, et al. How can we recognize continuous quality improvement? Int J Qual Health Care 2014;26:6-15.
18. Claassen CA, Pearson JL, Khodyakov D, Satow PM, Gebbia R, Berman AL, et al. Reducing the burden of suicide in the U.S.: the aspirational research goals of the National Action Alliance for Suicide Prevention Research Prioritization Task Force. Am J Prev Med 2014;47:309-14.
19. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, et al; Systemic Lupus Erythematosus Quality Indicators Project Expert Panels. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009;61:370-7.
20. Mangione-Smith R, De Cristofaro AH, Setodji CM, Keesey J, Klein DJ, Adams JL, et al. The quality of ambulatory care delivered to children in the United States. N Engl J Med 2007;357:1515-23.
21. Barber CE, Marshall DA, Alvarez N, Mancini GB, Lacaille D, Keeling S, et al. Development of cardiovascular quality indicators for rheumatoid arthritis: results from an international expert panel using a novel online process. J Rheumatol 2015;42:1548-55.
22. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, La Calle JR, Lazaro P, et al. The RAND/UCLA appropriateness method user's manual. [Internet. Accessed November 17, 2015.] Available from: www.rand.org/pubs/monograph-reports/MR1269.html
23. Albrecht K, Kruger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, et al; German Society of Rheumatology. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 2014;34:1-9.
24. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al; Canadian Rheumatology Association. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012; 39:1559-82.
25. Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, et al; British Society for Rheumatology; British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology 2009;48:436-9.
26. National Institute for Health and Clinical Excellence. Rheumatoid arthritis in adults: management. [Internet. Accessed November 17, 2015.] Available from: www.nice.org.uk/guidance/cg79
27. Scottish Intercollegiate Guidelines Network (SIGN). Management of early rheumatoid arthritis: a national clinical guideline. [Internet. Accessed November 17, 2015.] Available from: www.sign.ac.uk/guidelines/fulltext/123/index.html
28. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
29. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
30. Spanish Society of Rheumatology (SER). Update of the clinical practice guideline for the management of rheumatoid arthritis in Spain. [Internet. Accessed November 18, 2015.] Available from: www.ser.es/guipcar
31. The Royal Australian College of General Practitioners (RACGP). Clinical guideline for the diagnosis and management of early rheumatoid arthritis. [Internet. Accessed November 17, 2015.] Available from: www.racgp.org.au/download/documents/Guidelines/Musculoskeletal/racgp-ra-guideline.pdf
32. British Medical Association (BMA) and NHS Employers. Rheumatoid arthritis: the percentage of patients with rheumatoid arthritis, on the register, who have had a face-to-face review in the preceding 12 months. [Internet. Accessed November 17, 2015.] Available from: www.qualitymeasures.ahrq.gov/content.aspx?id=45469
33. Centers for Medicare and Medicaid Services. 2014 Physician Quality Reporting System (PQRS) measures specifications manual for claims and registry reporting of individual measures. [Internet. Accessed November 17, 2015.] Available from: www.google.ca/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&v ed=0CC0QFjAC&url=http%3A%2F%2Fwww.entnet.org%2Fsites %2Fdefault%2Ffiles%2FPQRS-Measures-Spec-Manual-Individuall-Measures-0.pdf&ei=TFEUVeGLAtCsyASr54CQAg&u sg=AFQjCNFzpjDnw4XZ00Zex5nVFqwsIAhmXg&bvm=bv.8938 1419,d.aWw
34. National Committee for Quality Assurance. Disease modifying anti-rheumatic drug therapy for rheumatoid arthritis. [Internet. Accessed November 17, 2015.] Available from: www.qualityforum.org
35. National Institute for Health Care Excellence (NICE). Quality standard for rheumatoid arthritis (QS33). [Internet. Accessed November 17, 2015.] Available from: publications.nice.org.uk/quality-standard-for-rheumatoid-arthritis-qs33
36. Petersson IF, Strombeck B, Andersen L, Cimmino M, Greiff R, Loza E, et al; eumusc.net-working group. Development of healthcare quality indicators for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis 2014;73:906-8.
37. American College of Rheumatology. Rheumatoid arthritis quality indicators. [Internet. Accessed November 17, 2015.] Available from: www.rheumatology.org/Practice-Quality/Clinical-Support/Quality-Measurement/ACR-Endorsed-Measures
38. Dernis E, Lavie F, Salliot C, Flipo RM, Saraux A, Maillefert JF, et al. Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine 2009;76:524-31.
39. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al; European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
40. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
41. Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. A national clinical guideline. [Internet. Accessed November 17, 2015.] Available from: sign.ac.uk/guidelines/fulltext/121/index.html
42. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
43. Agency for Healthcare Research and Quality. Espoguia (clinical guidelines for patients with spondyloarthritis). [Internet. Accessed November 17, 2015.] Available from: www.guideline.gov/content.aspx?id=33577&search=arthritis
44. Wendling D, Lukas C, Paccou J, Claudepierre P, Carton L, Combe B, et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine 2014;81:6-14.
45. Abad MÁ, Ariza RA, Aznar JJ, Batlle E, Beltrán E, de Dios Cañete J, et al. Standards of care for patients with spondyloarthritis. Rheumatol Int 2014;34:165-70.
46. The Royal Australian College of General Practitioners (RACGP). Clinical guideline for the diagnosis and management of juvenile idiopathic arthritis. [Internet. Accessed November 17, 2015.] Available from: www.nhmrc.gov.au/guidelines/publications/cp119
47. Davies K, Cleary G, Foster H, Hutchinson E, Baildam E; British Society of Paediatric and Adolescent Rheumatology. BSPAR Standards of Care for children and young people with juvenile idiopathic arthritis. Rheumatology 2010;49:1406-8.
48. Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, et al. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res 2011;63:10-6.
49. Canadian Rheumatology Association. Wait time benchmarks for arthritis care. [Internet. Accessed December 17, 2015.] Available from: www.waittimealliance.ca/benchmarks/arthritis-care/
50. Li LC, Badley EM, MacKay C, Mosher D, Jamal SW, Jones A, et al. An evidence-informed, integrated framework for rheumatoid arthritis care. Arthritis Rheum 2008;59:1171-83.